Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 17/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512921 | 1.00 | DHODH (0.45) | DHODHLCKFYNRORCTSHR | |
| SCHEMBL21462462 | 1.00 | DHODH (0.45) | DHODHLCKFYNRORCTSHR | |
| SCHEMBL24282513 | 0.90 | LCK (0.41) | DHODHLCKFYNTSHRHSD17B10 | |
| SCHEMBL30094015 | 0.90 | LCK (0.41) | DHODHLCKFYNTSHRHSD17B10 | |
| SCHEMBL20108192 | 0.90 | LCK (0.41) | DHODHLCKFYNTSHRHSD17B10 | |
| SCHEMBL20107634 | 0.89 | DHODH (0.43) | DHODHRORC | |
| SCHEMBL21435678 | 0.89 | DHODH (0.43) | DHODHRORC | |
| SCHEMBL29512864 | 0.89 | DHODH (0.43) | DHODHRORC | |
| SCHEMBL23213776 | 0.87 | DHODH (0.43) | DHODHRORC | |
| SCHEMBL24872644 | 0.87 | DHODH (0.43) | DHODHRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-01 | — | — | US | disclosed |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553052-A1 | 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer AG (DE) | 2019-10-16 | — | — | EP | disclosed |
| EP-3553052-A1 | 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer AG (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | Bayer Pharma AG (DE) | 2019-10-10 | — | — | US | disclosed |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | Bayer Pharma AG (DE) | 2019-10-10 | — | — | US | disclosed |
| WO-2018077944-A2 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018077923-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | DHODH 1/4885LCK 3353/4885FYN 4288/4885 |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DPYD, DHPS | DHODH 1/4885LCK 3168/4885FYN 4175/4885 |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | IDH3A, IDH3B, IDH2 | DHODH 161/4885LCK 316/4885FYN 970/4885 |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | DHODH 1/4885LCK 3353/4885FYN 4288/4885 |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | DHODH 1551/4885LCK 1388/4885FYN 3404/4885 |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DHPS, DPYD | DHODH 1/4885LCK 3353/4885FYN 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.